



FY 2021 RESULTS

March 16, 2022

DiaSorin

Disclaimer

In General. This disclaimer applies to this presentation and any oral comments of any person presenting it. This document, taken together with any such oral comments, is referred to herein as the “Presentation”. This Presentation has been prepared by DiaSorin S.p.A. (“DiaSorin” or the “Company” and, together with its subsidiary the “Group”). The Presentation is being furnished to you for information purposes only and for use in presentations of the industrial plan of the Group.

No distribution of this Presentation. This Presentation is being furnished to you solely for your information and may not be reproduced, in whole or in part, or redistributed to any other individual or legal entity.

Verbal explanation. This Presentation has to be accompanied by a verbal explanation. A simple reading of this Presentation without the appropriate verbal explanation could give rise to a partial or incorrect understanding.

No offer to purchase or sell securities. The information, statements and opinions contained in this Presentation are for information purposes only and do not constitute a public offer under any applicable legislation or an offer to sell or solicitation of an offer to purchase or subscribe for securities or financial instruments or any advice or recommendation with respect to such securities or other financial instruments.

Rounding. Due to rounding, numbers presented throughout this Presentation may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.

Miscellanea. This Presentation has been prepared on a voluntary basis. DiaSorin is therefore not bound to prepare similar presentations in the future, unless where provided by law. Neither the Company nor any member of the Group nor any of its or their respective representatives, directors, employees or agents accept any liability whatsoever in connection with this Presentation or any of its contents or in relation to any loss arising from its use or from any reliance placed upon it.

Piergiorgio Pedron, the manager responsible for the preparation of the company accounting documents for DiaSorin S.p.A., declares that, pursuant to Article 154-bis, paragraph 2, of the Legislative Decree February 24, 1998, no. 58, to the best of his knowledge, the accounting information included in this Presentation correspond to document results, books and accounting records.

Forward-looking statements

This document contains forward-looking statements that are based on current expectations, estimates, forecasts and projections about the industries in which DiaSorin operates and the beliefs and assumptions of the management of DiaSorin. In addition, the management of DiaSorin may make forward-looking statements orally to analysts, investors, representatives of the media and others. In particular, among other statements, certain statements regarding future financial performance, the achievement of certain targeted metrics at any future date or for any future period, trends in results of operations, margins, costs, return on capital, risk management and competition are forward-looking in nature. These statements may include terms such as “may”, “will”, “expect”, “could”, “should”, “intend”, “estimate”, “anticipate”, “believe”, “remain”, “on track”, “design”, “target”, “objective”, “goal”, “forecast”, “projection”, “outlook”, “prospects”, “plan”, or similar terms. Forward-looking statements are not guarantees of future performance and are, by their nature, subject to inherent risks, uncertainties and assumptions that are difficult to predict because they relate to events and depend on circumstances that may or may not occur or exist in the future and, as such, undue reliance should not be placed on them.

Forward-looking statements do not take into account any additional effects that may arise from impacts on the global market in which DiaSorin operates and, more generally, on the macroeconomic scenario, also following any eventual governmental measures related to the spread of COVID-19 and any potential delay in the vaccination campaign.

Actual results may differ materially from those expressed in forward-looking statements as a result of a variety of factors, including: the impact of the COVID-19 pandemic, the ability of the Group to create and launch new products successfully; changes in the global financial markets, general economic environment and changes in demand for diagnostic/healthcare/life sciences products, which is subject to cyclicity; changes in local economic and political conditions, changes in trade policy and the imposition of global and regional tariffs or tariffs targeted to the diagnostic/healthcare/life sciences industry, the enactment of tax reforms or other changes in tax laws and regulations; the Group’s ability to offer innovative, attractive products; various types of claims, lawsuits, governmental investigations and other contingencies, including product liability and warranty claims, investigations and lawsuits; material operating expenditures in relation to compliance with health and safety regulations; the intense level of competition in the diagnostic/healthcare/life sciences industry, which may increase due to consolidation; the Group’s ability to fund its defined benefit pension plans; the ability to access funding to execute its business plans and improve its own businesses, financial condition and results of operations; the Group’s ability to realize anticipated benefits from joint venture arrangements; disruptions arising from political, social and economic instability; commercial risk due to the fact that the Group operates in a market characterized by the presence of large competitors; risk associated to the maintenance of relationship with customers and strategic partners; risks associated with relationships with employees and suppliers; increases in costs, disruptions of supply or shortages of raw materials; developments in labor and industrial relations and developments in applicable labor laws; exchange rate fluctuations, interest rate changes, credit risk and other market risks; political and civil unrest; earthquakes or other disasters.

Any forward-looking statements contained in this document speak only as of the date of this document and DiaSorin disclaim any obligation to update or revise publicly forward-looking statements. Further information concerning the Group and its business, including factors that could materially affect the Group’s financial results, are included in DiaSorin’s reports and filings with CONSOB and Borsa Italiana.

No update. The information and opinions in this document is provided to you as of the dates indicated and DiaSorin does not undertake to update the information contained in this document and/or any opinions expressed relating thereto after its presentation, even in the event that the information becomes materially inaccurate, except as otherwise required by applicable laws.

Non-IFRS and Other Performance Measures. This document contains certain items as part of the financial disclosure, which are not defined under IFRS. Accordingly, these items do not have standardized meanings and may not be directly comparable to similarly-titled items adopted by other entities. DiaSorin management has identified a number of “Alternative Performance Indicators” (“APIs”). These APIs (i) are derived from historical results of DiaSorin and are not intended to be indicative of future performance, (ii) are non-IFRS financial measures and, although derived from the financial statements, are unaudited and (iii) are not an alternative to financial measures prepared in accordance with IFRS. The APIs presented herein include EBIT¹, EBITDA², adjusted EBITDA³, Net Financial Position⁴ and Free Cash Flow⁵. These measures are not indicative of historical operating results, nor are they meant to be predictive of future results. These measures are used by the management to monitor the underlying performance of the business and operations. Similarly entitled non-IFRS financial measures reported by other companies may not be calculated in an identical manner, consequently the measures reported in this document may not be consistent with similar measures used by other companies. Therefore, investors should not place undue reliance on this data.

¹ EBIT is defined as the “Operating Result” net of interests and taxes – ² EBITDA is defined as the “Operating Result”, gross of amortization and depreciation of intangible and tangible assets. EBITDA is a measure used by the Company to monitor and evaluate the Group’s operating performance and is not defined as an accounting measure in IFRS and therefore shall not be considered an alternative measure for assessing the Group’s operating result performance. - ³ Adjusted EBITDA is defined as Adjusted EBITDA, excluding extraordinary costs and expenses incurred in the Luminex transaction announced on April 11, 2021 - ⁴ The Net Financial Position is defined as the algebraic sum (positive balance sheet assets and negative balance sheet liabilities) of cash and cash equivalents and other current financial assets, minus current financial liabilities and non-current financial liabilities.-⁵ Free Cash Flow is defined as the set of means available to the Company and is equal to cash flows deriving from operating activities net of interest received or paid, and net of investments and divestments of fixed assets.

Financial Highlights*

Data in €/mln	FY'21	Change	
		@ current	@ CER
Revenues	1,237.7	+40.4%	+41.2%
CLIA ex Vitamin D		+24.0%	+24.5%
Vitamin D (CLIA)		+7.8%	+9.4%
ELISA tests		-14.0%	-13.0%
Molecular tests		+27.4%	+29.3%
Instruments & Others		-3.1%	-2.5%
Luminex	195.0	<i>n.m.</i>	<i>n.m.</i>
Adjusted EBITDA	543.1	+41.0%	+41.8%
<i>Adjusted EBITDA Margin</i>	43.9%	+16 bps	+19 bps
Adjusted EBIT	465.1	+43.5%	
<i>Adjusted EBIT Margin</i>	37.6%	+79 bps	
Adjusted Net Result	356.9	+43.8%	
<i>% on revenues</i>	28.8%	+67 bps	
Free Cash Flow	300.7		
Net Financial Debt	-985.9		

* With reference to the Adjusted EBITDA, Adjusted EBIT and Adjusted Net Profit indicators, please refer to the table included in the financial schemes section of this presentation

FY 2021 key facts

Business Development

- **Luminex acquisition:** the closing of the transaction is effective starting from July 14, 2021. Through the acquisition, DiaSorin gained access to Luminex's multiplexing technology and a portfolio that will strengthen its existing offering, while expanding its presence in the U.S. market. The acquisition also provided access to Luminex's applications throughout the Life Science industry

Convertible bond loan to complete the acquisition of Luminex

- Placement of an **unsecured equity-linked senior bond loan for € 500 million with maturity to 2028** aimed at completing the acquisition of Luminex Corporation, completed on July 14, 2021. On October 4, 2021, **the Extraordinary Shareholders' Meeting authorized the convertibility of the equity-linked bond** and the share capital increase

Product Development

Immunodiagnosics

- **LIAISON® SARS-CoV-2 TrimericS IgG:** a quantitative test for the determination of IgG antibodies, developed using the full length SARS-CoV-2 Spike protein in its Trimeric form, *CE marked and approved through Food and Drug Administration (FDA) Emergency Use Authorization in the U.S. as a semi-quantitative test*
- **LIAISON® Lyme IgG and LIAISON® Lyme IgM** tests approved by the U.S. FDA for Lyme Borreliosis detection through identification of IgG and IgM antibodies
- **LIAISON® SARS-CoV-2 Ag:** for the identification and qualitative detection of SARS-CoV-2 viral load through nasal and nasopharyngeal swabs (*CE marked and now approved through FDA Emergency Use Authorization in the U.S.*)
- **LIAISON® IQ** Point-of-Care (POC) platform **and LIAISON® Quick Detect COVID TrimericS Ab:** new immunoassay POC platform and its first test to detect IgG antibodies against SARS-CoV-2 on nasal and nasopharyngeal swabs (*CE marked*)
- **LIAISON® LymeDetect:** test based on QuantiFERON technology and developed in partnership with QIAGEN, for the early diagnosis of Lyme Borreliosis (*CE marked*)
- **LIAISON® Quick Detect COVID Ag:** new antigen test for the detection of COVID-19 infection available on the immunodiagnostic POC Platform LIAISON® IQ (*CE marked*)
- **LIAISON® Murex Anti-HEV IgG & IgM,** the first CLIA fully automated high-throughput solution for the diagnosis of Hepatitis E (*CE marked*)
- **LIAISON® MeMed BV** the first high throughput blood test to differentiate between bacterial and viral infections (*CE marked*)
- **LIAISON® QuantiFERON®-TB Gold Plus** assay received FDA approval for its use on the LIAISON® XS Analyzer

Molecular Diagnostics

- **Simplexa™ SARS-CoV-2 Variants Direct Assay (Research Use Only)** for the detection and discrimination of 4 SARS-CoV-2 mutations associated with circulating virus variants without requiring upfront RNA extraction
- **Simplexa™ COVID-19 & Flu A/B Direct Assay** for the qualitative detection and differentiation of SARS-CoV-2 and Influenza A and influenza B virus from the same patient sample in one reaction well (*CE Marked*)

Life Science


- **xMAP® Intelliflex (Research Use Only)** a modern, compact, flow based multiplexing platform, combining the proven performance of xMAP Technology with modern features to enhance performance, empower assay development innovation, and simplify your user experience. It is the only Multiplex platform combining low- and high-plex capabilities, quick time to reliable results, and the ability to simultaneously acquire data for two parameters per analyte

Managerial outlook on FY 2021 revenues

Total FY Group revenues (data in €/mln)

Data @CER

Data @CUR



Evolution of the business in the quarter

Positive results, driven by three separate trends:

- **BUSINESS EX-COVID** (at constant perimeter[§]): on a strong recovery path, +14.8% @CER vs. FY'20, with growth trends across all geographies
- **TOTAL COVID-19 TESTS CONTRIBUTION** in 2021 equals to € 378 million (€ 381 million at *constant exchange rates*), € 342 million (€ 346 million at *constant exchange rates*) with reference to DiaSorin ex-Luminex[§], with specific reference to the U.S., Canada and Europe
- **LUMINEX CONTRIBUTION**: first 6 months' contribution equals to € 195 million at current exchange rates

[§]Excluding Luminex, acquired on July 14, 2021 and incorporated within the Group perimeter starting from its acquisition

FY 2021 revenue growth by geography and technology

BY GEOGRAPHY [§]	FY'21 vs. FY'20
EUROPE & AFRICA <ul style="list-style-type: none"> Positive top line trend, thanks to the contribution of COVID-19 testing and the recovery of ex-COVID sales. 	+25.9%
USA & CANADA <ul style="list-style-type: none"> Positive performance of ex-COVID sales (Latent Tuberculosis test, the GI Panel and the Hepatitis & Retrovirus panel) Positive contribution of the COVID-19 testing 	+12.0%
ASIA PACIFIC <ul style="list-style-type: none"> Positive performance of all CLIA tests' and instruments' sales 	+16.4%
LATIN AMERICA <ul style="list-style-type: none"> Positive contribution of serology COVID testing and strong recovery in ex-COVID business 	+31.4%
LUMINEX	€ 195.0 mln


BY TECHNOLOGY [§]	FY'21 vs. FY'20
CLIA EX VITAMIN D TESTS <ul style="list-style-type: none"> reported @ CER 	+24.0% +24.5%
VITAMIN D TEST (CLIA) <ul style="list-style-type: none"> reported @ CER 	+7.8% +9.4%
ELISA TESTS <ul style="list-style-type: none"> reported @ CER 	-14.0% -13.0%
MOLECULAR DIAGNOSTIC TESTS <ul style="list-style-type: none"> reported @ CER 	+27.4% +29.3%
INSTRUMENTS & OTHER REVENUES <ul style="list-style-type: none"> reported @ CER 	-3.1% -2.5%
LUMINEX	€ 195.0 mln

[§]Excluding Luminex, acquired on July 14, 2021 and incorporated within the Group perimeter since acquisition
 Change YoY @ CER, Luminex contribution is disclosed at current exchange rates

FY 2021 revenues: managerial view


BY GEOGRAPHY

FY'21



BY TECHNOLOGY

FY'21




Luminex Revenues' trend

- **EXCELLENT PERFORMANCE**, of both the **MOLECULAR BUSINESS** on the Aries® and Verigene® platforms, and the **LICENSED TECHNOLOGIES** business, that in H2'21 recorded an overall increase of about 20% *proforma*° vs. H2'20
- **POSITIVE CONTRIBUTION** of the **SALES OF ARIES® COVID TESTS**, partially offset by a reduction in Non-Automated Assays products due to lower sales of COVID products which had peaked in 2020

° Consolidated 2020 data including Luminex

FY'21 profitability profile

(data in €/mln)



- Luminex acquisition had an expected dilutive effect on the Group profitability profile in H2, that will progressively decline over the next quarters as a consequence of the integration process and its related synergies

* With reference to the Adjusted EBITDA please refer to the table included in the financial schemes section of this presentation

FY 2022 Company Guidance

FY 2022 GUIDANCE at 2021 CER:

- **REVENUES:** ex-COVID revenues growing at +24.0%, COVID-19 related products revenues at € 150 million, resulting in total revenues broadly in line with 2021 (approx. -2% vs. FY'21)
- **ADJUSTED EBITDA* MARGIN:** *approx. 35%*

* With reference to the Adjusted EBITDA please refer to the table included in the financial schemes section of this presentation



Financial schemes

Income Statement

(Amounts in million of euros)	FY		Change	
	2020	2021	amount	%
Net Revenues	881.3	1,237.7	+356.4	+40.4%
Cost of sales	(278.4)	(412.9)	-134.5	+48.3%
Gross profit	602.9	824.8	+221.9	+36.8%
	68.4%	66.6%	-177 bps	
Sales and marketing expenses	(144.1)	(211.3)	-67.3	+46.7%
Research and development costs	(50.8)	(70.1)	-19.3	+38.0%
General and administrative expenses	(72.1)	(93.3)	-21.2	+29.4%
Total operating expenses	(266.9)	(374.7)	-107.8	+40.4%
	30.3%	30.3%	-1 bps	
Other operating income (expense)	(11.7)	(30.6)	-18.8	<i>n.m.</i>
<i>non recurring amount</i>	(3.7)	(21.9)	-18.2	<i>n.m.</i>
EBIT	324.2	419.5	+95.3	+29.4%
	36.8%	33.9%	-290 bps	
Net financial income (expense)	(2.9)	(20.2)	-17.3	<i>n.m.</i>
Profit before taxes	321.4	399.3	+78.0	+24.3%
Income taxes	(73.1)	(88.6)	-15.5	+21.2%
Net result	248.3	310.7	+62.4	+25.1%
EBITDA²	385.3	515.5	+130.2	+33.8%
	43.7%	41.7%	-206 bps	

² EBITDA is defined as the "Operating Result", gross of amortization and depreciation of intangible and tangible assets. EBITDA is a measure used by the Company to monitor and evaluate the Group's operating performance and is not defined as an accounting measure in IFRS and therefore shall not be considered an alternative measure for assessing the Group's operating result performance.

Adjusted Income Statement*

(Amounts in million of euros)	FY		Change	
	2020	2021	amount	%
Net Revenues	881.3	1,237.7	+356.3	+40.4%
Cost of sales	(278.4)	(406.7)	-128.3	+46.1%
Gross profit	602.9	831.0	+228.1	+37.8%
	68.4%	67.1%	-127 bps	
Sales and marketing expenses	(144.1)	(197.1)	-53.0	+36.8%
Research and development costs	(50.8)	(66.3)	-15.5	+30.4%
General and administrative expenses	(72.1)	(93.3)	-21.2	+29.4%
Total operating expenses	(266.9)	(356.6)	-89.7	+33.6%
	30.3%	28.8%	-147 bps	
Other operating income (expense)	(11.7)	(9.2)	+2.5	-21.7%
EBIT	324.2	465.1	+140.9	+43.5%
	36.8%	37.6%	+79 bps	
Net financial income (expense)	(2.9)	(4.4)	-1.6	+55.0%
Profit before taxes	321.4	460.7	+139.3	+43.4%
Income taxes	(73.1)	(103.8)	-30.7	+42.0%
Net result	248.3	356.9	+108.6	+43.8%
EBITDA²	385.3	543.1	+157.8	+41.0%
	43.7%	43.9%	+16 bps	

² EBITDA is defined as the "Operating Result", gross of amortization and depreciation of intangible and tangible assets. EBITDA is a measure used by the Company to monitor and evaluate the Group's operating performance and is not defined as an accounting measure in IFRS and therefore shall not be considered an alternative measure for assessing the Group's operating result performance.

* With reference to the Adjusted measures please refer to the table at the next slide

Reconciliation to consolidated financial statements

<i>Data in €/mln</i>	Gross Margin	EBITDA ²	EBIT	Fiscal Impact	Net Profit
IFRS Financial Statements Measures	824.8	515.5	419.5	n.a.	310.7
% on Revenues	66.6%	41.7%	33.9%		25.1%
Adjustments					
<i>Fair value</i> measurement of the initial Luminex inventory	6.2	6.2	6.2	(1.5)	4.7
"One-off" Costs related to the acquisition, integration and restructuring of Luminex	-	21.4	21.4	(5.1)	16.3
Depreciation of Luminex intangibles identified in the Purchase Price Allocation	-	-	18.1	(4.4)	13.6
Financial charges relating to debt instruments and to the convertible bond issued to finance the acquisition	-	-	-	(4.1)	11.6
Total Adjustments	6.2	27.6	45.6	(15.2)	46.2
Adjusted Measures	831.0	543.1	465.1	n.a.	356.9

The alternative performance measures listed in the table should be used as an information supplement to the provisions of IFRS, to assist users of the document in better understanding the economic, equity and financial performance of the Group. Such measures are computed purifying the results of the one-off costs relating to the acquisition and integration of Luminex, of the amortization deriving from the Purchase Price Allocation and of the financial charges associated with the financing of the transaction, including the tax impact. It should also be noted that the method of calculating these adjusted indicators could differ from the methods used by other companies.

² EBITDA is defined as the "Operating Result", gross of amortization and depreciation of intangible and tangible assets. EBITDA is a measure used by the Company to monitor and evaluate the Group's operating performance and is not defined as an accounting measure in IFRS and therefore shall not be considered an alternative measure for assessing the Group's operating result performance.

Balance Sheet

<i>(Amounts in million of euros)</i>	12/31/2020	12/31/2021	Change
Goodwill and intangibles assets	356.7	1,943.4	+1,586.6
Property, plant and equipment	140.5	276.2	+135.7
Other non-current assets	35.3	42.6	+7.3
Net working capital	217.9	361.9	+144.0
Other non-current liabilities	(99.5)	(270.2)	-170.8
Net Invested Capital	651.0	2,353.8	+1,702.9
Net Financial Debt	305.3	(985.9)	-1,291.2
Total shareholders' equity	956.3	1,367.9	+411.6

Cash flow statement

<i>(Amounts in million of euros)</i>	FY	
	2020	2021
Cash and cash equivalents at the beginning of the period	157.6	339.9
Cash provided by operating activities	304.6	400.7
Cash used in investing activities	(73.0)	(110.4)
Cash provided/(used) in financing activities	(90.0)	1,273.7
Acquisitions of companies and business operations	-	(1,500.8)
Net change in cash and cash equivalents before investments in financial assets	141.5	63.1
Divestment/(Investment) in financial assets	40.8	-
Net change in cash and cash equivalents	182.3	63.1
Cash and cash equivalents at the end of the period	339.9	403.0

DiaSorin

